Tjalma WAA, et al. - Researchers compared subcutaneous (SC) trastuzumab (herceptin) vs intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer in terms of time and cost differential. A substantial reduction in active health care professional (HCP) time, patient chair time, unit time, and overall cost were observed in association with SC administration of trastuzumab. In a lean operating day dare oncology unit, these time and cost could be used to increase capacity within existing resources.